London: Britain’s competition regulator para khobor te koikena janaishe ki tai khan para hundreds nishena pounds khan kurishe fine te alag alag pharmaceutical nimete etu bi kanoon ke breach kuribole nimete etu hydrocortisone tablets diya nimete.
Etu Competition and Markets Authority (CMA) para koikena janaishe tai khan para 260 million ($361 million, 305 million euros) uporte penalties khan kurishe companies khan te etu state-run National Health Service (NHS) aro market te diya nimete.
regulator’s investigation te paishe ki Auden Mckenzie and its successor Actavis UK – etia Accord-UK –laga naam para jaana toh NHS ke charge kurishe hydrocortisone tablets nimete bishi daam kura nimete bishi sal te para.
Etu te koikena janaishe Auden Mckenzie potential competitors AMCo – ke dishe etia Advanz Pharma — and Waymade ke market para bahart te thakibole nimete etu bi position toh bachabole nimete tablet laga provider thaka nimete.
Actavis UK toh AMCo ke di thakishe etu bi hydrocortisone laga bekah te sabole nimete 201 te.CMA para koikena janaidiya thakishe.
Life saving tablets laga damaoth 10000 percent para uthise etu samay te etu toh regulator para 2008 aro 2018 majhotte kura toh.
Britain te hazaar nishena manu khan tablet te steroid te depend kuri thakishe etu adrenal insufficiency sabole nimete etu te debilitating conditions Addison’s disease khan ase.
CMA para accord Uk ke fine kurishe aro tai khan laga ownership periuonds nimete tai khan lga parent companies Intas and Accord and its former parent firm Allergan –155 million overcharging nimete thakishe.
Etu para Accord-UK and Allergan 66 million te uthise etu bi dui diubole dibo etu market para bahar te thakibole nimete.
Etia tai khan laga collision part nimete cma para advanz ke penalize kurishe aro tai khan laga former former parent Cinven — a 43 million levy aro Waymade 2.5 million te.
